Retatrutide®
Achieve your weight goals with the power of Retatrutide®
Achieve your weight goals with the power of Retatrutide®
Retatrutide is a new medicine being investigated for its potential effectiveness in treating obesity and type 2 diabetes. Retatrutide, manufactured by Eli Lilly and Company, is still in the research phase, but preliminary results indicate a positive effect.
Because retatrutide is currently in the research phase, it cannot yet be purchased. It is expected to be a prescription-only medicine, like other weight-loss medications, meaning it will only be available with a doctor's prescription.
The price of retatrutide will be determined later by the pharmacist.
| Products: | Retatrutide® | Mounjaro® | Ozempic® | Wegovy® |
|---|---|---|---|---|
| Pharmacist: | Eli Lilly | Eli Lilly | Novo Nordisk | Novo Nordisk |
| Active ingredient: | Retatrutide | Tirzepatide | Semaglutide | Semaglutide |
| Treatment type: | Obesity and type 2 diabetes | Obesity and Type 2 Diabetes | Type 2 Diabetes | Obesity |
| Dosage: | - | 2,5 - 15mg | 0.25 - 2.4mg | 0.25 - 2.4mg |
| Administration: | Injection, 1x per week | Injection, 1x per week | Injection, 1x per week | Injection, 1x per week |
| Approval phase: | Research phase | Approved | Approved | Approved |
| Side effects: | No overview of possible side effects known yet | Common side effects include: nausea, diarrhea, decreased appetite, abdominal pain, reflux. | Common side effects include: nausea, diarrhea, vomiting, constipation, abdominal pain | Common side effects include: nausea, diarrhea, vomiting, constipation, abdominal pain |
Retatrutide will likely be indicated for adult patients with an initial BMI (Body Mass Index) of: ≥ 30 BMI (obesity), or ≥ 27 BMI to < 30 BMI (overweight) who have at least one weight-related comorbidity, such as diabetes, high blood pressure, high cholesterol, osteoarthritis, or sleep apnea. The final indication will follow once the medicine is approved.
Retatrutide is only available by prescription from a doctor if the patient meets the indications described above. However, the research phase still needs to be completed, and it is not yet clear whether and when it will enter the Dutch market.
Retatrutide is a medicine that affects 3 hormone receptors: the GLP-1 hormone, Glucagon, and GIP hormone. These help regulate blood glucose levels, contribute to insulin secretion, aid in hunger and satiety, stimulate fat burning, and thereby the energy balance.
Retatrutide has not yet been approved by the FDA and the Ministry of Health. The medicine is still in the research phase and therefore cannot yet receive approval.
The action of tirzepatide is dual, and the action of retatrutide is triple.
The medicine retatrutide has not yet been approved by the FDA and the Ministry of Health. Therefore, it cannot yet be said whether it will be reimbursed in the future.
The dosages of retatrutide during studies are 1 mg, 2 mg, 4 mg, 8 mg, and 12 mg. Which dosages will be available in the future depends on further research and approval from the FDA and the Ministry of Health.
Retatrutide is administered via a subcutaneous injection. Do not inject it into a vein or muscle. The best places to inject are:
